Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe

Circulation Journal

Volumn 77, Issue 6, 2013, Pages 1518-1525

  Daida, Hiroyuki ^a   Iwase, Takayuki ^b   Yagi, Shigeru ^b   Ando, Hidekazu ^b   Nakajima, Hiromu ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Development and Medical Affairs Division   (Japan)

Author keywords

Atherosclerosis; Darapladib; Dyslipidemia; Lipoprotein associated phospholipase A2; V279F

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 11 OXOTHROMBOXANE B2; C REACTIVE PROTEIN; DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PLACEBO;

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE GENE; ABNORMAL FECES; ADULT; AGED; ARTICLE; BLOOD PRESSURE; COLORIMETRY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ECZEMA; FEMALE; FOLLOW UP; GENE; GENOTYPE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ODOR; UPPER ABDOMINAL PAIN; URINE ODOR; VAL279PHE GENE;

ADULT; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; BENZALDEHYDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; MUTATION, MISSENSE; OXIMES; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878252122     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0813     Document Type: Article

References (34)

1. Miyauchi K, Daida H. Clinical signifcance of intensive lipid-lower-ing therapy using statins in patients with coronary artery disease: LDL-cholesterol: The lower, the better; is it true for Asians? (Pro) Circ J 2010; 74: 1718-1730.
2. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intra-vascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
3. Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, et al. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy: The extended JAPAN-ACS study. Circ J 2012; 76: 825-832.
4. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justifcation for Atherosclerosis Regression Treatment (JART) study. Circ J 2012; 76: 221-229.
5. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phos-pholipase A2 as a target of therapy. Curr Opin Lipidol 2005; 16: 442-446.
6. Zalewski A, Macphee C. Role of lipoprotein-associated phospholi-pase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931.
7. McCullough P. Darapladib and atherosclerotic plaque: Should lipo-protein-associated phospholipase A2 be a therapeutic target? Curr Atheroscler Rep 2009; 11: 334-337.
8. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010; 160: 655-661.
9. Satoh N, Asano K, Naoki K, Fukunaga K, Iwata M, Kanazawa M, et al. Plasma platelet-activating factor acetylhydrolase defciency in Japanese patients with asthma. Am J Respir Crit Care Med 1999; 159: 974-979.
10. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. Platelet-activating factor acetylhydrolase defcien-cy: A missense mutation near the active site of an anti-infammatory phospholipase. J Clin Invest 1996; 97: 2784-2791.
11. Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: The Beijing atherosclerosis study. Hum Genet 2009; 125: 11-20.
12. Jang Y, Kim OY, Koh SJ, Chae JS, Ko YG, Kim JY, et al. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006; 91: 3521-3527.
13. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279--> Phe) is a genetic risk factor for stroke. Stroke 1997; 28: 2417-2420.
14. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetyl-hydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000; 66: 1522-1530.
15. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospho-lipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-1544.
16. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-842.
17. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005; 111: 570-575.
18. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myo-cardial Infarction) trial. Circulation 2006; 113: 1745-1752.
19. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26: 137-144.
20. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066.
21. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipopro-tein-associated phospholipase A2 activity and cardiovascular bio-markers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51: 1632-1641.
22. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-1182.
23. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of infammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26: 1586-1593.
24. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholi-pase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc 2007; 82: 159-165.
25. Stafforini DM, Tjoelker LW, McCormick SPA, Vaitkus D, McIntyre TM, Gray PW, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low-density lipo-protein. J Biol Chem 1999; 274: 7018-7024.
26. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773.
27. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-2273.
28. Benitez S, Sanchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, González-Sastre F, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein sub-fraction. Circulation 2003; 108: 92-96.
29. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dys-lipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22: 306-311.
30. Tsimihodimos V, Kakafka A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, et al. Fenofbrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipopro-teins. J Lipid Res 2003; 44: 927-934.
31. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 2005; 182: 193-198.
32. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: A placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 1153-1159.
33. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospho-lipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005; 95: 1025-1032.
34. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, et al. Differential effect of hypolipidemic drugs on lipo-protein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-2243.